Drug Safety Newsletter – Edition 111 – 13 March 2023
13/03/2023
Medicines for human use
Safety update
The latest edition of the HPRA Drug Safety Newsletter (edition 111) includes important updates to support the safe and appropriate use of the following medicines:
Levothyroxine: Biotin interference with thyroid function tests, and drug-drug interaction between levothyroxine and St. John’s Wort and proton-pump inhibitors (PPIs)
Levonorgestrel-containing products: Factors associated with increased risk of expulsion and update on risks associated with intrauterine exposure.
IMBRUVICA® (ibrutinib): New risk minimisation measures, including dose modification recommendations, due to increased risk of serious cardiac events.
Product information updates recommended by the EMA's Pharmacovigilance Risk Assessment Committee (PRAC)